Literature DB >> 26744560

Letters to the Editor.

I Mitchell1, B Paes2, K Lanctot3, Rupesh Chawla4, Aaron Chiu5, Marianna Mitchell6, Cecil Ojah7, April Price8, Sandra Seigel9, Amanda Symington10.   

Abstract

Year:  2015        PMID： 26744560      PMCID： PMC4699533          DOI： 10.1093/pch/20.8.463

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  26 in total

1.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

2.  Palivizumab prophylaxis: does it have any influence on the growth and development of the infants?

Authors:  Ismail Tavsu; Tugba Gursoy; Sukriye Dirman; Nazan Erbil; Fahri Ovali
Journal:  Am J Perinatol       Date:  2013-09-10       Impact factor: 1.862

Review 3.  Epidemiology of bronchopulmonary dysplasia.

Authors:  Erik A Jensen; Barbara Schmidt
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03-17

4.  Preventing respiratory syncytial virus infections.

Authors:  Jl Robinson
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

5.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

6.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

Authors:  K N Subramanian; L E Weisman; T Rhodes; R Ariagno; P J Sánchez; J Steichen; L B Givner; T L Jennings; F H Top; D Carlin; E Connor
Journal:  Pediatr Infect Dis J       Date:  1998-02       Impact factor: 2.129

7.  Respiratory syncytial virus-associated mortality in hospitalized infants and young children.

Authors:  Carrie L Byington; Jacob Wilkes; Kent Korgenski; Xiaoming Sheng
Journal:  Pediatrics       Date:  2014-12-08       Impact factor: 7.124

Review 8.  The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection.

Authors:  Shelagh M Szabo; Katherine L Gooch; Meagan M Bibby; Pamela G Vo; Ian Mitchell; Pamela Bradt; Adrian R Levy
Journal:  Paediatr Respir Rev       Date:  2013-01       Impact factor: 2.726

Review 9.  Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Authors:  Colleen Wegzyn; Lim Kai Toh; Gerard Notario; Sophie Biguenet; Kristina Unnebrink; Caroline Park; Doris Makari; Michael Norton
Journal:  Infect Dis Ther       Date:  2014-10-09

10.  A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study.

Authors:  Eric A F Simões; Xavier Carbonell-Estrany; John R Fullarton; Johannes G Liese; Jose Figueras-Aloy; Gunther Doering; Juana Guzman
Journal:  Respir Res       Date:  2008-12-08
View more
  1 in total

1.  Reducing the burden of lower respiratory tract infections in infants in the Canadian Arctic.

Authors:  Ian Mitchell; Delshani Peiris
Journal:  CMAJ       Date:  2017-03-27       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.